コンテンツへスキップ
Merck
  • Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease.

Successful alternative treatment containing vindesine for acute lymphoblastic leukemia with Charcot-Marie-Tooth disease.

Journal of pediatric hematology/oncology (2012-01-17)
Mizuho Ichikawa, Daisuke Suzuki, Jun Inamoto, Junjiro Ohshima, Yuko Cho, Shinji Saitoh, Makoto Kaneda, Akihiro Iguchi, Tadashi Ariga
要旨

Peripheral neuropathy is a well-known side effect of vincristine (VCR), a microtubule inhibitor commonly used to treat malignancies. Severe neurological adverse events can occur in patients with Charcot-Marie-Tooth disease (CMT) treated with VCR. Vindesine is also a microtubule inhibitor, which, like VCR, is widely used to treat malignancies. The case of an 11-year-old female patient with CMT type 1A who developed severe peripheral neuropathy induced by VCR given for her acute lymphoblastic leukemia is reported. Alternative treatment containing vindesine instead of VCR led to a successful outcome without a relapse of leukemia or neurological worsening of CMT.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
Vindesine sulfate salt hydrate, ≥95% (HPLC)